Filing Flows › GSK (GSK) › How it makes money
How GSK (GSK) makes money
GSK (GSK) made $8.6B of revenue in the third quarter 2026 (Q3 2026). Specialty Medicines brought in $3.9B (45%); Dolutegravir products brought in $1.4B (17%); Dovato brought in $754M (9%). Of every dollar of revenue, 74¢ was left as gross profit, 30¢ was left as operating profit, 24¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Specialty Medicines | $3.9B | 45.3% | — | — |
| ↳ HIV | $2.1B | 24.7% | — | — |
| ↳ Respiratory, Immunology & Inflammation | $1.1B | 13.3% | — | — |
| ↳ Oncology | $622M | 7.3% | — | — |
| Dolutegravir products | $1.4B | 16.9% | — | — |
| Dovato | $754M | 8.8% | — | — |
| Long Acting Injectables | $621M | 7.3% | — | — |
| Nucala | $582M | 6.8% | — | — |
| Benlysta | $520M | 6.1% | — | — |
| ↳ Tivicay | $319M | 3.7% | — | — |
| ↳ Triumeq | $201M | 2.4% | — | — |
| Cabenuva | $478M | 5.6% | — | — |
| Jemperli | $273M | 3.2% | — | — |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $8.6B | 100.0% |
| Cost of revenue | $2.3B | 26.4% |
| Gross profit | $6.3B | 73.6% |
| Operating expenses | $3.7B | 43.2% |
| Operating profit | $2.6B | 30.3% |
| Income tax | $312M | 3.6% |
| Net earnings | $2.0B | 23.5% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $8.5B | — |
| Q2 2026 | $8.4B | +5% |
From GSK's 6-K filed Oct 28, 2026 (on EDGAR).
Questions
How does GSK make money?
GSK (GSK) made $8.6B of revenue in the third quarter 2026 (Q3 2026). Specialty Medicines brought in $3.9B (45%); Dolutegravir products brought in $1.4B (17%); Dovato brought in $754M (9%). Of every dollar of revenue, 74¢ was left as gross profit, 30¢ was left as operating profit, 24¢ was left as net earnings.
What is GSK's biggest business?
Specialty Medicines: $3.9B in the third quarter 2026, 45% of revenue.
What is GSK's profit margin?
Net earnings were $2.0B, 23.5% of revenue, in the third quarter 2026; the operating margin was 30.3%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.